Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
June 17, 2019

AstraZeneca’s Lokelma shows significant effect in ESRD trial

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has achieved statistically significant and clinically meaningful improvement in treating hyperkalaemia in patients with end-stage renal disease (ESRD) on haemodialysis in phase 111b Dialize trial.

Image: AstraZeneca’s Lokelma has showed significant effect in end-stage renal disease trial. Photo: courtesy of AstraZeneca.